|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility.
|
10439311 |
1999 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Circulating autoantibodies to pancreatic glutamic acid decarboxylase (GAD65; the 65-kDa isoform of glutamic acid decarboxylase), protein tyrosine phosphatase-like protein IA-2, and insulin can be used as predictive markers of type 1 diabetes.
|
12765988 |
2003 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes.
|
23780460 |
2013 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Differences in autoantibody binding to wild-type GAD65 versus GAD65-E517P may provide predictive information about Type 1 diabetes risk beyond that provided by the presence or absence of GAD65 autoantibodies.
|
15365614 |
2004 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
DNA vaccination of HLA-transgenic mice may be another rapid and efficient reverse immunology approach to map additional epitopes derived from other T1DM Ags, such as IA-2 and glutamic acid decarboxylase 65 (GAD 65).
|
17130554 |
2006 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Epitope preferences of different mAbs to GAD65 aligned with different clinical expressions of type 1 diabetes.
|
18184926 |
2008 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Epitope profiles of autoantibodies to GAD65 (GADA) in 140 type 1 diabetes, adult-onset diabetes mellitus (AODM), and thyroid diseases (TD) were studied.
|
12865069 |
2003 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
For the subjects diagnosed as T1D, mean C-peptide was 0.63 ± 0.51 nmol/L (1.91 ± 1.53 ng/mL), with 16 (16.2%) IA2 positive, 53 (53.5%) GAD-65 positive, and 10 (10.1%) positive for both autoantibodies.
|
30710658 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, donor islet exosome cargo analysis showed time-specific increase in islet autoantigen, glutamic acid decarboxylase 65 (GAD65), implicated in T1D autoimmunity.
|
30801971 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, evidence is presented that autoantibodies to GAD65 in IDDM sera react with an epitope formed on a dimeric configuration of the molecule.
|
9892508 |
1998 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
LHGDN |
GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients.
|
18487477 |
2008 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
GADA affinity was measured by competitive binding experiments with [(125)I]-labeled and -unlabeled recombinant human GAD65 in the first GADA-positive sample from 95 children with a type 1 diabetes family history who were prospectively followed from birth and in follow-up samples from 65 of these children.
|
17325256 |
2007 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
GIMAP5 polymorphism was not associated with type I diabetes or with GAD65 or insulin autoantibodies, ICA, or age at clinical onset in patients.
|
17641683 |
2007 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Given the evidence that GAD67 could be a key diabetogenic autoantigen in the NOD mouse and the high prevalence of GAD65 autoantibodies in human type 1 diabetes, it became important to ask whether there is also immune reactivity to GAD25 in type 1 diabetes-possibly implicating it in the pathogenesis of the disease-and whether GAD25 reactivity could, like GAD65 reactivity, function as a clinically useful marker for the disease.
|
12515288 |
2002 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Glutamate cysteine ligase catalytic subunit promoter polymorphisms and associations with type 1 diabetes age-at-onset and GAD65 autoantibody levels.
|
17479437 |
2007 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Glutamic acid decarboxylase (GAD)-alum (Diamyd(®), Diamyd Medical, Stockholm, Sweden) is an adjuvant-formulated vaccine incorporating recombinant human GAD65, the specific isoform of GAD expressed in human pancreatic β-cells and a major antigen targeted by autoreactive T lymphocytes in Type 1 diabetes mellitus.
|
21395375 |
2011 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we show that autoreactive CD8<sup>+</sup> Tscm specific for β-cell antigens GAD65, insulin, and IGRP are present in patients with type 1 diabetes (T1D).
|
29506985 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we describe the construction of recombinant L. lactis secreting the 65 kDa isoform of glutamic acid decarboxylase (GAD65) and tyrosine phosphatase-like protein ICA512 (IA-2), two major T1D-related auto-antigens.
|
25576592 |
2015 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Herein, we have tested the therapeutic potential of a soluble HLA-DR4-GAD65 271-280 (hu DEF-GAD65) chimera of human use in a newly-generated NOD/DR4/B7 double transgenic (dTg) mouse that develops spontaneously an accelerated T1D regardless the gender.
|
24335553 |
2014 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HLA genotypes were determined in offspring of parents with Type I diabetes who were followed from birth for at least 2 years (median follow-up: 3.1 years) and who were characterised for the expression of insulin, GAD65, IA-2 and islet cell autoantibodies at birth, 9 months, 2 and 5 years of age.
|
10382586 |
1999 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
HLA-DR3-DQ2<sup>+</sup>huCD4<sup>+</sup>IA/IE<sup>-/-</sup>RIP.B7.1<sup>+</sup> mice spontaneously developed autoimmune diabetes (incidence 46% by 35 weeks of age), accompanied by numerous hallmarks of human type 1 diabetes (autoantibodies against GAD65 and proinsulin; pancreatic islet infiltration by CD4<sup>+</sup>, CD8<sup>+</sup> B220<sup>+</sup>, CD11b<sup>+</sup> and CD11c<sup>+</sup> immune cells).
|
31612266 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Humans with type 1 diabetes had a lower frequency and diminished function of CD52(hi)CD4(+) T cells responsive to the autoantigen GAD65.
|
23685786 |
2013 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
IAA, ICA, GAD(65)A, IA-2A and HLA- class II alleles were determined in 546 first-degree-relatives, 244 siblings, 55 offspring and 233 parents of 178 Brazilian patients with T1DM.
|
22402866 |
2012 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Immunodominant GAD65 epitopes defined in transgenic mice correspond to GAD65 regions previously shown to elicit T cell responses specifically in DR0401 IDDM patients, underscoring the validity of this approach.
|
9223318 |
1997 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In competition analysis with unlabeled purified recombinant human islet GAD65, binding to tracer was inhibited in 74% (74 of 100) of the GAD65-positive IDDM serum samples compared with 2% of the control samples.
|
8314020 |
1994 |